Lucosky Brookman LLP Successfully Represents HeartBeam, Inc. in $16.5 Million Initial Public Offering
Lucosky Brookman LLP congratulates its client, Heartbeam, Inc. (Nasdaq: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology to bring new capabilities to cardiovascular disease, on its successful initial public offering of $16.5 million common stock and warrants. The company announced the pricing of its initial public offering of 2,750,000 units, each consisting of (i) one share of common stock and (ii) one warrant to purchase a share of common stock, at a public offering price per unit of $6.00. The warrants have an exercise price of $6.00 per share and are exercisable for a period of five years after the issuance date.
Lucosky Brookman acted as corporate and securities counsel to the Company, while The Benchmark Company, LLC acted as sole book-running manager for the offering.
The gross proceeds to HeartBeam from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $16.5 million. HeartBeam expects to use the net proceeds from the offering to fund: its initial product, the ER product, including the achievement of FDA 510(k) clearance and commercial launch; engineering and regulatory work for its telehealth product, to achieve FDA 510(k) clearance of the telehealth product and to commercialize the product; and working capital and general corporate purposes.